Stelara Injection Articles
Study finds potential use of ustekinumab for Crohn's disease
18 October 2012
More news at EULAR from Novartis, J&S and B-MS
7 June 2012
Highlights from Digestive Disease Week
11 May 2011
Abbott/Eisai's Humira emerges as market leader in psoriatic arthritis, garnering sales of over $500 million in 2009
5 November 2010
Psoriasis drug market expected to double to $6.8 Billion in 2019, driven by biologics penetration and Interleukin/TNF-alpha inhibitors
10 August 2010
Despite minimal uptake in Crohn's market, Stelara's premium price will result in nearly $337 million sales in 2018 and briakinumab $130 million
23 February 2010
Increasing competition from other biologics will continue to erode Enbrel's dominance in the psoriasis drug market, DR report concludes
12 February 2010
UK’s NICE says “no” to Novartis’ Afinitor for advanced RCC and delays Sprycel and Tasigna; Scotland backs Alimta and Stelara
9 February 2010
Janssen-Cilag's Stelara backed by UK’s NICE for moderate-to-severe plaque psoriasis
23 September 2009
Highlights of first PDCO meeting of 2009
26 January 2009
Stock Commentary - New York week to Dec 15, 2008
22 December 2008
Medarex gets milestone from Centocor for Stelara
22 December 2008
Janssen's mixed bag from CHMP meeting
1 December 2008
FDA extends review of BLA for ustekinumab
18 August 2008
J&J psoriasis candidate may cause cancer; FDA
23 June 2008
FDA expert panel votes to approve Centocor
23 June 2008
Centocor's psoriasis drug accepted for FDA review
10 March 2008
Ustekinumab: "gold standard" for psoriasis by 2011
18 February 2008
Ustekinumab boosts 12-week PASI-75 scores
11 February 2008
Ustekinumab submitted for marketing review in EU and USA
17 December 2007
Ustekinumab helps patients achieve PASI-75
15 October 2007
Showing 1-28 of 28 articles
- 1
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
